NASDAQ:FOLD - Amicus Therapeutics Stock Price, News, & Analysis

Amicus Therapeutics trades on the NASDAQ under the ticker symbol "FOLD."

Amicus Therapeutics, Inc. (NASDAQ:FOLD) posted its earnings results on Tuesday, August, 7th. The biopharmaceutical company reported ($0.33) EPS for the quarter, beating the Zacks' consensus estimate of ($0.33) by $0.00. The biopharmaceutical company had revenue of $21.31 million for the quarter, compared to analysts' expectations of $18.92 million. Amicus Therapeutics had a negative return on equity of 53.45% and a negative net margin of 460.04%. View Amicus Therapeutics' Earnings History.

Amicus Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, November, 14th 2018. View Earnings Estimates for Amicus Therapeutics.

7 analysts have issued 12 month price objectives for Amicus Therapeutics' shares. Their forecasts range from $15.00 to $24.00. On average, they expect Amicus Therapeutics' stock price to reach $19.6667 in the next twelve months. This suggests a possible upside of 49.4% from the stock's current price. View Analyst Price Targets for Amicus Therapeutics.

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Amicus Therapeutics in the last year. There are currently 2 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Amicus Therapeutics.

Amicus Therapeutics saw a increase in short interest in July. As of July 31st, there was short interest totalling 25,418,562 shares, an increase of 3.7% from the July 13th total of 26,395,013 shares. Based on an average trading volume of 1,720,366 shares, the short-interest ratio is presently 14.8 days. Currently, 13.8% of the shares of the company are sold short. View Amicus Therapeutics' Current Options Chain.

Some companies that are related to Amicus Therapeutics include Jazz Pharmaceuticals (JAZZ), Nektar Therapeutics (NKTR), Genmab A/S (GNMSF), Alnylam Pharmaceuticals (ALNY), Perrigo (PRGO), Beigene (BGNE), Sarepta Therapeutics (SRPT), Valeant Pharmaceuticals (VRX), Bausch Health Companies (BHC), SAGE Therapeutics (SAGE), Alkermes (ALKS), Ionis Pharmaceuticals (IONS), GALAPAGOS NV/S (GLPG), United Therapeutics (UTHR) and Catalent (CTLT).

Media coverage about FOLD stock has trended somewhat positive recently, according to Accern Sentiment Analysis. The research group identifies positive and negative media coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Amicus Therapeutics earned a media and rumor sentiment score of 0.13 on Accern's scale. They also assigned news coverage about the biopharmaceutical company an impact score of 46.63 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company's share price in the near future. View Recent Headlines for Amicus Therapeutics.

Amicus Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional investors include BlackRock Inc. (8.50%), FMR LLC (7.15%), Redmile Group LLC (5.56%), Jennison Associates LLC (5.36%), Janus Henderson Group PLC (4.34%) and Morgan Stanley (2.63%). Company insiders that own Amicus Therapeutics stock include Bradley L Campbell, Daphne Quimi, Donald J Hayden Jr, Hung Do, Jay Barth, John F Crowley, Kurt J Andrews, Life Sciences Maste Perceptive, Margaret G Mcglynn, Michael Raab, Perceptive Advisors Llc and William D Baird III. View Institutional Ownership Trends for Amicus Therapeutics.

FOLD stock was sold by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, Jennison Associates LLC, Redmile Group LLC, Eagle Asset Management Inc., Asymmetry Capital Management L.P., Voya Investment Management LLC, Delek Group Ltd. and BNP Paribas Arbitrage SA. Company insiders that have sold Amicus Therapeutics company stock in the last year include Bradley L Campbell, Daphne Quimi, Donald J Hayden Jr, Hung Do, Jay Barth, John F Crowley, Kurt J Andrews, Margaret G Mcglynn, Michael Raab and William D Baird III. View Insider Buying and Selling for Amicus Therapeutics.

FOLD stock was bought by a variety of institutional investors in the last quarter, including Morgan Stanley, Novo Holdings A S, BlackRock Inc., Point72 Asset Management L.P., Emerald Advisers Inc. PA, Victory Capital Management Inc., Emerald Mutual Fund Advisers Trust and Tavio Capital LLC. Company insiders that have bought Amicus Therapeutics stock in the last two years include John F Crowley, Life Sciences Maste Perceptive and Perceptive Advisors Llc. View Insider Buying and Selling for Amicus Therapeutics.

Shares of FOLD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of FOLD stock can currently be purchased for approximately $13.16.

Amicus Therapeutics has a market capitalization of $2.90 billion and generates $36.93 million in revenue each year. The biopharmaceutical company earns $-284,000,000.00 in net income (profit) each year or ($2.92) on an earnings per share basis. Amicus Therapeutics employs 325 workers across the globe.

Amicus Therapeutics' mailing address is 1 Cedar Brook Drive, Cranbury NJ, 08512. The biopharmaceutical company can be reached via phone at 609-662-2000 or via email at [email protected]